乾癬治療薬の世界市場予測2016-2026

◆英語タイトル:Psoriasis Drugs Market Forecasts 2016-2026
◆商品コード:VGAIN60710
◆発行会社(調査会社):visiongain
◆発行日:2016年6月
◆ページ数:170
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥283,858見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥425,858見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥709,858見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、乾癬治療薬の世界市場について調査・分析し、乾癬治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
1. レポート概要

2. 乾癬の概要

3. 乾癬治療薬の世界市場 2016-2026

4. 乾癬治療市場における主要治療薬 2016-2026

5. 主要国の乾癬治療市場 2016-2026

6. 乾癬治療薬研究開発パイプライン 2016

7. 乾癬治療薬市場における主要企業 2016

8. 乾癬治療薬市場の定性分析 2016-2026

9. 結論
【レポートの概要】

Psoriasis Drugs – Your Guide to R&D, Opportunities and Potential Revenues
What does the future hold for treating psoriasis? Visiongain’s new report gives you multilevel revenue forecasts from 2016, helping you stay ahead in data. There you see financial results, R&D trends, opportunities and potential revenues.

In our study you examine predicted sales to 2026 at overall world market, submarket, product and national level. You also assess technologies, competitive forces and expected products. That work’s purpose is to help you avoid falling behind in knowledge, missing business or losing influence.

So read on now to explore that industry and discover what its future market could be worth. See how our investigation can benefit your work.

Forecasts from 2016 to 2026 and other analyses to help you harness opportunities
Why miss data you need? Why struggle to find it? Instead let our analysis guide you through the psoriasis drug market’s present and future. That understanding could bring you quicker, easier results, also benefiting your influence and reputation for business insight.

Besides revenue forecasting to 2026, our new work shows you recent results, growth rates and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). In our 169 page study you gain 74 tables and 63 charts to benefit your research, analyses, plans, decisions and presentations.

The following sections outline what you get in our updated investigation.

Sales predictions for the world market and submarkets
What is that industry’s potential? Discover in our report overall world revenue to 2026 for psoriasis-treating medicines. First you see individual revenue forecasts to 2026 for three main submarkets at world level:
• Biological drugs
• Topical treatments
• Small-molecule systemic therapies.

How will those segments’ revenues expand? Which classes of treatment will generate most sales? There you assess prospects for revenue growth, seeing where you can gain, assessing how that industry will compete and develop.

You find revenue predictions by product, too, seeing from 2016 how they can succeed.

Revenue predictions for 13 products to 2026 – discover what their futures hold
How will individual drugs perform from 2016 to 2026 at world level? Our report forecasts revenues of established brands and medicines expected from 2016.

In our work you assess 13 drugs, including these brands:
• Humira (adalimumab)
• Stelara (ustekinumab)
• Enbrel (etanercept)
• Remicade (infliximab)
• Otezla (apremilast)

There you discover how high sales can go, to 2026, finding drugs and years with highest predicted growth and revenues. You also examine trends and competition. You see what is happening, understanding challenges, progress, competitors and opportunities.

You find geographical revenue predictions too.

National markets – where will highest revenues and growth occur?
In developed and developing countries, opportunities in psoriasis treatment will occur from 2016. You see where and how pharma companies can develop and gain.

Our analyses show individual revenue forecasts to 2026 for these 11 national markets:
• US and Japan
• France, Germany, Italy, Spain and UK
• Brazil, Russia, India and China.

There you find countries with highest revenues and potential sales growth. You assess that technology’s future, seeing progress and finding what it means, including emerging trends for those skin disorder treatments.

Events affecting developers, producers and sellers – issues shaping that industry
Our report explains forces affecting that industry and market from 2016, including these influences:
• Research and development, including monoclonal antibodies, IL-12, IL-17, IL-23, PDE4, TNF, JAK and T-cell inhibition, and histamine receptor antagonism
• Prevalence of that skin disease, as well as issues for patients and healthcare providers – assess treatment needs
• Competition from generic drugs, biosimilars and new biologics
• Companies specialising in dermatology and autoimmune disorders – explore capabilities and emerging trends to treat psoriasis
• Advances in drug delivery to benefit companies, patients and payers, including lotion, ointment and foam.

In our survey you explore political, economic, social and technological questions, assessing outlooks for business. You also examine that pharmaceutical segment’s strengths, weaknesses, opportunities and threats.

That way you discover what the present and future hold, seeing what is possible for those drug developers, producers and marketers. Stay ahead in knowledge.

Companies leading that industry and our overall revenue prediction for 2020
From 2016, treatments for psoriasis hold potential for investments, medical advances and higher revenues. Our work predicts the overall world market for psoriasis medicines will reach $11.4bn in 2020, with further expansion to 2026.

See what is possible there – the expected gains. Our report shows you what technologies and firms hold greatest potential. You explore activities of these companies, among others:
• Johnson & Johnson
• AbbVie
• Amgen
• Pfizer
• Novartis
• Celgene
• LEO Pharma.

Our analysis shows you participants’ results, capabilities, developments and outlooks. R&D in that industry is strong. From 2016 the psoriasis market holds many opportunities for revenue growth. Our work explains that potential, helping you stay ahead in knowledge.

Main ways Psoriasis Drugs Market Forecasts 2016-2026 helps your work
In particular our new investigation gives you these advantages to benefit your research, analyses, decisions, proposals and presentations:
• Revenues to 2026 at world level, with forecasting of 3 submarkets and 13 products – assess prospects for investments and sales growth
• Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia – investigate leading countries for revenues and expected sales
• Forces driving and restraining that industry’s expansion – discover what influences revenue gain, finding trends, developments and opportunities
• Prospects for established competitors and rising companies – explore companies’ portfolios, results, R&D and outlooks for future success.

【レポートの目次】

1. Report Overview
1.1 Psoriasis Overview
1.2 Psoriasis Market Segmentation
1.3 Why You Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report for?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQ)
1.9 Some Associated Reports
1.10 About Visiongain

2. Introduction to Psoriasis
2.1 Understanding Skin
2.2 What is Psoriasis?
2.3 What Causes Psoriasis?
2.3.1 Genetic Factors
2.3.2 Environmental Factors
2.4 World Prevalence of Psoriasis
2.5 How is Psoriasis Treated?
2.5.1 Biologic Drugs
2.5.2 Small Molecule Systemic Drugs
2.5.3 Topical Therapies
2.6 Classification of Severity

3. The World Drug Market for Psoriasis 2016-2026
3.1 The World Drug Market for Psoriasis in 2015: Biologic Drugs Dominate In Terms of Revenue
3.2 The World Drug Market for Psoriasis: Overarching Revenue Forecast 2016-2026
3.3 The World Drug Market for Psoriasis by Therapeutic Subclass: Comparison of Revenues and Market Shares to 2026
3.4 The World Drug Market for Psoriasis by Therapeutic Subclass: Grouped Revenue Forecast 2016-2026
3.5 Biologic Drugs for Psoriasis: Blockbuster Revenue for 2015
3.5.1 Biologic Drugs for Psoriasis: Revenue Forecast, 2016-2026
3.6 Topical Therapies for Psoriasis: The Most Commonly Prescribed Treatments
3.6.1 Topical Therapies for Psoriasis: Revenue Forecast, 2016-2026
3.7 Small Molecule Systemic Treatments for Psoriasis: A Subclass with Promise
3.7.1 Small Molecule Systemic Treatments for Psoriasis: Revenue Forecast, 2016-2026

4. Leading Drugs of the Psoriasis Treatment Market, 2016-2026
4.1 The Leading Drugs on the Market in 2015: Three Drugs Achieved Blockbuster Success
4.2 Leading Psoriasis Drugs: Comparison of Revenues and Market Shares, 2021 and 2026
4.3 Leading Psoriasis Drugs: Grouped Forecasts 2016-2026
4.4 Humira: Blockbuster Revenue from Psoriasis Indications 2015
4.4.1 Threat from Biosimilars
4.4.2 Humira: Revenue Forecast 2016-2026
4.5 Stelara: A Strong Performer in Psoriasis
4.5.1 Competition for Stelara in the Pipeline
4.5.2 Stelara: Revenue Forecast, 2016-2026
4.6 Enbrel: Facing Competition from Biosimilars
4.6.1 Sales of Enbrel in 2015
4.6.2 Patent Expiries
4.6.3 Threat from Biosimilars
4.6.4 Enbrel: Revenue Forecast, 2016-2026
4.7 Remicade: Facing a Declining Market Share
4.7.1 Threat from Biosimilars
4.7.1.1 Inflectra/Remsima: First Infliximab Biosimilar
4.7.1.2 Flixabi: Biosimilar from Samsung Bioepis
4.7.2 Remicade: Revenue Forecast, 2016-2026
4.8 Otezla: A Promising New Therapy
4.8.1 Otezla: Revenue Forecast, 2016-2026
4.9 Daivobet: A Widely Prescribed Topical Treatment
4.9.1 Daivobet: Revenue Forecast, 2016-2026
4.10 Soriatane: Generic Competition Eroding Sales
4.10.1 Soriatane: Revenue Forecast, 2016-2026
4.11 Cosentyx: First IL-17 Inhibitor on the Market
4.11.1 Cosentyx: Revenue Forecast, 2016-2026
4.12 Simponi: Growth Limited by its Indications
4.12.1 Simponi: Revenue Forecast, 2016-2026
4.13 Tazorac: Facing Competition from Generics
4.13.1 Tazorac: Revenue Forecast, 2016-2026
4.14 Promising Compounds in the Pipeline
4.14.1 Taltz: Second IL-17 Inhibitor to Reach the Market
4.14.1.1 Taltz: Revenue Forecast 2016-2026
4.14.2 Tildrakizumab: Positive Phase III Data
4.14.2.1 Tildrakizumab: Revenue Forecast 2016-2026
4.14.3 Guselkumab: Promising IL-23 Inhibitor
4.14.3.1 Guselkumab: Revenue Forecast 2016-2026

5. Leading National Markets for Psoriasis Treatment, 2016-2026
5.1 The Leading National Markets in 2015: The US Dominates the Psoriasis Market
5.2 The Leading National Markets: Comparison of Revenues and Market Shares to 2026
5.3 The Leading National Markets: Grouped Revenue Forecasts 2016-2026
5.4 The US: Large Population and Large Financial Resources Mean There is a Large Market for Psoriasis Drugs
5.4.1 The US Psoriasis Drug Market: Revenue Forecast 2016-2026
5.5 The EU Psoriasis Drug Market: 2015-2026
5.5.1 The Psoriasis Drug Market in Germany: Revenue Forecast 2016-2026
5.5.2 The Psoriasis Drug Market in France: Revenue Forecast 2016-2026
5.5.3 The Psoriasis Drug Market in the UK: Revenue Forecast 2015-2026
5.5.4 The Psoriasis Drug Market in Italy: Revenue Forecast 2015-2026
5.5.5 The Psoriasis Drug Market in Spain: Revenue Forecast 2015-2026
5.6 Japan: The Second Largest National Market in 2015
5.6.1 The Psoriasis Drug Market in Japan: Revenue Forecast 2015-2026
5.7 China: The Psoriasis Drug Market is Growing Steadily
5.7.1 The Psoriasis Drug Market in China: Revenue Forecast 2015-2026
5.8 India: Low Healthcare Spending Limits Sales
5.8.1 The Psoriasis Drug Market in India: Revenue Forecast 2015-2026
5.9 Russia: Experiencing Troubled Times
5.9.1 The Psoriasis Drug Market in Russia: Revenue Forecast 2015-2026
5.10 Brazil: Encouraging Domestic Manufacturers
5.10.1 The Psoriasis Drug Market in Brazil: Revenue Forecast 2015-2026

6. Psoriasis R&D Pipeline, 2016
6.1 Biologics
6.1.1 Brodalumab: Less Promising Than Expected
6.1.2 BI 655066: First IL-23 to Reach the Market?
6.1.3 Cimzia: Potential Licence Expansion to Psoriasis
6.1.4 Orencia: Efficacy in Psoriasis and Psoriatic Arthritis?
6.1.5 ABT-122: A Dual Action Molecule
6.1.6 Namilumab: Novel Mechanism of Action
6.1.7 Biosimilars: The Growing Threat to Biologics
6.2 Small Molecule Systemic Treatments
6.2.1 Xeljanz: Approval in the Balance
6.2.2 CF-101: Efficacy in Question
6.2.3 Baricitinib: Janus Kinase Inhibitor
6.2.4 JNJ 168: Histamine Receptor Antagonist
6.2.5 Prurisol: Will its Phase II Study Succeed?
6.3 Topical Molecules
6.3.1 IDP-118 Lotion: Combines Steroid and Retinoid
6.3.2 M518101 Ointment: Phosphodiesterase Inhibitor
6.3.3 122-0551 Foam: Steroid-Based Product

7. Leading Companies in the Psoriasis Drug Market, 2016
7.1 The Leading Companies in the Market
7.2 Johnson & Johnson: Top Performer in Psoriasis
7.3 AbbVie: Highly Reliant on Humira
7.4 Amgen: Actively Developing Biosimilars
7.5 Pfizer: Hospira Acquisition Boosts Biosimilar Portfolio
7.6 LEO Pharma: Specialises in Dermatology
7.7 Celgene: Sales Boosted by Otezla
7.8 Novartis: Cosentyx Performing Well
7.9 GSK: Looking to Expand Their Immunology Portfolio
7.10 Merck: A Limited Share of the Market

8. Qualitative Analysis of the Psoriasis Market, 2016-2026
8.1 Strengths and Weaknesses of the Psoriasis Drug Market, 2016-2026
8.1.1 Strengths of High Patient Demand, Active Research and High Revenue Potential
8.1.2 Weaknesses from Shortcomings of Current Treatments and Patent Expiries
8.2 The Opportunities and Threats Facing the Psoriasis Drug Market, 2016-2026
8.2.1 Opportunities of Patient Demand for Improved Treatments
8.2.2 Threats from Financial Restrictions and Market Saturation
8.3 Social, Technological, Economic and Political Factors Influencing the Psoriasis Drug Market (STEP analysis), 2016-2026
8.3.1 Social Factors Influencing the Market
8.3.2 Technological Factors Affecting the Psoriasis Drug Market
8.3.3 Economic Impact of Psoriasis Treatment
8.3.4 Political Considerations Influencing Drug Approval
8.3.4.1 Biosimilar Approval in Developed Countries
8.3.4.2 Biosimilar Approval in Developing Countries

9. Conclusions
9.1 The World Market Value for Psoriasis Drugs, 2016-2026
9.2 Leading Drugs of the Psoriasis Treatment Market, 2016-2026
9.3 Leading National Markets for Psoriasis Drugs, 2016-2026
9.4 Leading Companies in the Market
9.5 Trends in the Psoriasis Drugs Market

List of Tables
Table 2.1 Biologic Drugs Indicated for the Treatment of Psoriasis, 2016
Table 2.2 Small Molecule Systemic Drugs Indicated for the Treatment of Psoriasis, 2016
Table 2.3 Topical Treatments Indicated for the Treatment of Psoriasis, 2016
Table 3.1 The Psoriasis Drug Market by Therapeutic Class: Revenue ($m) and Market Share (%), 2015
Table 3.2 The World Drug Market for Psoriasis: Revenue Forecast ($m), 2015-2026
Table 3.3 The World Drug Market for Psoriasis by Therapeutic Subclass: Revenue ($m) and Market Share (%) Predictions, 2021 and 2026
Table 3.4 The World Drug Market for Psoriasis by Therapeutic Subclass: Revenue Forecasts ($m), 2015-2026
Table 3.5 Biologic Drugs for Psoriasis: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 3.6 Topical Treatments for Psoriasis: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 3.7 Small Molecule Systemic Treatments for Psoriasis: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 4.1 The Top Ten Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2015
Table 4.2 Leading Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2021 and 2026
Table 4.3 Leading Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2015-2021
Table 4.4 Leading Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2022-2026
Table 4.5 Humira: Key Facts
Table 4.6 Humira: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.7 Stelara: Key Facts
Table 4.8 Stelara: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.9 Enbrel: Key Facts
Table 4.10 Enbrel: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.11 Remicade: Key Facts
Table 4.12 Remicade: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.13 Otezla: Key Facts
Table 4.14 Otezla: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.15 Daivobet: Key Facts
Table 4.16 Daivobet: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.17 Soriatane: Key Facts
Table 4.18 Soriatane: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.19 Cosentyx: Key Facts
Table 4.20 Cosentyx: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.21 Simponi: Key Facts
Table 4.22 Simponi: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.23 Tazorac: Key Facts
Table 4.24 Tazorac: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.25 Taltz: Key Facts
Table 4.26 Taltz: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.27 Tildrakizumab: Key Facts
Table 4.28 Tildrakizumab: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.29 Guselkumab: Key Facts
Table 4.30 Guselkumab: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.1 The Leading National Markets for Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2015
Table 5.2 The Leading National Markets for Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2021 and 2026
Table 5.3 The Leading National Markets for Psoriasis Drugs: Grouped Revenue Forecasts ($m), 2015-2021
Table 5.4 The Leading National Markets for Psoriasis Drugs: Grouped Revenue Forecasts ($m), 2022-2026
Table 5.5 The US Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.6 The EU5 Psoriasis Drug Markets: Grouped Revenue Forecasts ($m), 2015-2026
Table 5.7 The German Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.8 The French Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 5.9 The Psoriasis Drug Market in the UK: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 5.10 The Psoriasis Drug Market in Italy: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 5.11 The Psoriasis Drug Market in Spain: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 5.12 The Psoriasis Drug Market in Japan: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 5.13 The Psoriasis Drug Market in China: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 5.14 The Psoriasis Drug Market in India: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 5.15 The Psoriasis Drug Market in Russia: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 5.16 The Psoriasis Drug Market in Brazil: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 6.1 Biologic Drugs in the Pipeline for Psoriasis and Psoriatic Arthritis, 2016
Table 6.2 Biosimilar Drugs in Development
Table 6.3 Small Molecule Systemic Drugs in the Pipeline for Psoriasis and Psoriatic Arthritis, 2016
Table 6.4 Topical Treatments in the Pipeline for Psoriasis and Psoriatic Arthritis, 2016
Table 7.1 The Leading Companies in the Psoriasis Drug Market: Revenue ($m) and Market Share (%), 2015
Table 7.2 J&J: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
Table 7.3 AbbVie: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
Table 7.4 Amgen: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
Table 7.5 Pfizer: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
Table 7.6 Leo Pharma: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
Table 7.7 Celgene: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
Table 7.8 Novartis: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
Table 7.9 GSK: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
Table 7.10 Merck: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2015
Table 8.1 Strengths and Weaknesses of the Psoriasis Drug Market, 2016-2026
Table 8.2 Opportunities and Threats Facing the Psoriasis Drug Market, 2016-2026
Table 8.3 Social, Technological, Economic and Political Factors Influencing the Psoriasis Drug Market (STEP analysis), 2016-2026
Table 9.1 Drivers and Restraints of the Psoriasis Drug Market, 2016-2026

List of Figures
Figure 1.1 Main Segments and Sub-Segments of the Psoriasis Market, 2016
Figure 3.1 The Psoriasis Drug Market by Therapeutic Class: Market Shares (%), 2015
Figure 3.2 The World Drug Market for Psoriasis: Revenue Forecast ($m), 2015-2026
Figure 3.3 The World Drug Market for Psoriasis by Therapeutic Subclass: Market Shares (%), 2021
Figure 3.4 The World Drug Market for Psoriasis by Therapeutic Subclass: Market Shares (%), 2026
Figure 3.5 Biologic Drugs: Share (%) of the Psoriasis Market, 2015
Figure 3.6 Biologic Drugs for Psoriasis: Revenue Forecast ($m), 2015-2026
Figure 3.7 Topical Treatments: Share (%) of the Psoriasis Market, 2015
Figure 3.8 Topical Treatments for Psoriasis: Revenue Forecast ($m), 2015-2026
Figure 3.9 Small Molecule Systemic Treatments: Share (%) of the Psoriasis Market, 2015
Figure 3.10 Small Molecule Systemic Treatments: Revenue ($m) Forecast, 2015-2026
Figure 4.1 The Leading Psoriasis Drugs: Market Shares (%), 2015
Figure 4.2 The Leading Psoriasis Drugs: Market Shares (%), 2021
Figure 4.3 The Leading Psoriasis Drugs: Market Shares (%), 2026
Figure 4.4 Humira Revenue Forecast ($m), 2015-2026
Figure 4.5 Stelara Revenue Forecast ($m), 2015-2026
Figure 4.6 Enbrel Revenue Forecast ($m), 2015-2026
Figure 4.7 Remicade Revenue Forecast ($m), 2015-2026
Figure 4.8 Otezla: Revenue Forecast ($m), 2015-2026
Figure 4.9 Daivobet: Revenue Forecast ($m), 2015-2026
Figure 4.10 Soriatane Revenue Forecast ($m), 2015-2026
Figure 4.11 Cosentyx Revenue Forecast ($m), 2015-2026
Figure 4.12 Simponi Revenue Forecast ($m), 2015-2026
Figure 4.13 Tazorac Revenue Forecast ($m), 2015-2026
Figure 4.14 Taltz: Revenue Forecast ($m), 2015-2026
Figure 4.15 Tildrakizumab: Revenue Forecast ($m), 2015-2026
Figure 4.16 Guselkumab: Revenue Forecast ($m), 2015-2026
Figure 5.1 The Leading National Markets for Psoriasis Drugs: Market Shares (%), 2015
Figure 5.2 The Leading National Markets for Psoriasis Drugs: Market Shares (%), 2021
Figure 5.3 The Leading National Markets for Psoriasis Drugs: Market Shares (%), 2026
Figure 5.4 The US Psoriasis Drug Market: World Market Share (%), 2015
Figure 5.5 The US Psoriasis Drug Market: Revenue Forecast ($m), 2015-2026
Figure 5.6 The EU5 Psoriasis Drug Market: World Market Share (%), 2015
Figure 5.7 The EU5 Psoriasis Drug Market: Revenue Forecast ($m), 2015-2026
Figure 5.8 The German Psoriasis Drug Market: Revenue Forecast ($m), 2015-2026
Figure 5.9 The French Psoriasis Drug Market: Revenue Forecast ($m), 2015-2026
Figure 5.10 The UK Psoriasis Drug Market: Revenue Forecast ($m), 2015-2026
Figure 5.11 The Psoriasis Drug Market in Italy: Revenue Forecast ($m), 2015-2026
Figure 5.12 The Psoriasis Drug Market in Spain: Revenue Forecast ($m), 2015-2026
Figure 5.13 The Psoriasis Drug Market in Japan: World Market Share (%), 2015
Figure 5.14 The Psoriasis Drug Market in Japan: Revenue Forecast ($m), 2015-2026
Figure 5.15 The Psoriasis Drug Market in China: World Market Share (%), 2015
Figure 5.16 The Psoriasis Drug Market in China: Revenue Forecast ($m), 2015-2026
Figure 5.17 The Psoriasis Drug Market in India: World Market Share (%), 2015
Figure 5.18 The Psoriasis Drug Market in India: Revenue Forecast ($m), 2015-2026
Figure 5.19 The Psoriasis Drug Market in Russia: World Market Share (%), 2015
Figure 5.20 The Psoriasis Drug Market in Russia: Revenue Forecast ($m), 2015-2026
Figure 5.21 The Psoriasis Drug Market in Brazil: World Market Share (%), 2015
Figure 5.22 The Psoriasis Drug Market in Brazil: Revenue Forecast ($m), 2015-2026
Figure 7.1 The Leading Companies in the Psoriasis Drug Market: Market Shares (%), 2015
Figure 7.2 J&J: Breakdown of Revenue by Indication (%), 2015
Figure 7.3 AbbVie: Breakdown of Revenue by Indication (%), 2015
Figure 7.4 Amgen: Breakdown of Revenue by Indication (%), 2015
Figure 7.5 Pfizer: Breakdown of Revenue by Indication (%), 2015
Figure 7.6 Leo Pharma: Breakdown of Revenue by Indication (%), 2015
Figure 7.7 Celgene: Breakdown of Revenue by Indication (%), 2015
Figure 7.8 Novartis: Breakdown of Revenue by Indication (%), 2015
Figure 7.9 GSK: Breakdown of Revenue by Indication (%), 2015
Figure 7.10 Merck: Breakdown of Revenue by Indication (%), 2015
Figure 9.1 The World Market for Psoriasis Drugs by Therapeutic Category ($m), 2016-2026
Figure 9.2 The Leading Drugs of the Psoriasis Drug Market: Comparison of Revenue ($m), 2016, 2021 and 2026
Figure 9.3 The Leading National Markets: Comparison of Revenue ($m), 2016, 2021 and 2026
Figure 9.4 The Leading Companies in the Market: Comparison of Revenue Generated by Sales of Drugs for Psoriasis ($m), 2015

★調査レポート[乾癬治療薬の世界市場予測2016-2026]販売に関する免責事項
★調査レポート[乾癬治療薬の世界市場予測2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆